Welcome to our dedicated page for Pacific Software news (Ticker: PFSF), a resource for investors and traders seeking the latest updates and insights on Pacific Software stock.
Pacific Software Inc. (PFSF) has issued news over several years that reflects a notable evolution in its business focus, from restaurant development to skincare, dietary supplements, and neuromedicine. Earlier announcements describe the company as a restaurant developer and brand incubator with joint ventures and ownership stakes in fast-casual and family-style concepts in the United States. More recent releases highlight a pivot toward patented cosmeceutical technology, science-based brain health products, and precision neuromedicine.
News items detail Pacific Software’s acquisition of Dermatrix, a patented cosmeceutical asset originally developed by Dreamaderm Inc., and an exclusive licensing agreement with the Regents of the University of California for peptide inhibitors of insulin-degrading enzyme (IDE) tailored for dermatological applications. These stories explain how Dermatrix is associated with collagen production, wound healing, and cosmetic procedures.
Additional coverage focuses on the acquisition of a science-based dietary supplement for brain health and memory function marketed as SuppleMEM AD™ and A.L.Z. Defense™. Press releases describe the formula as a medical food cocktail evaluated in NIH-funded laboratory experiments at the University of California, Irvine and the University of Kentucky, and discuss Pacific Software’s plans to manufacture and distribute the product in the United States and Mexico.
The latest news introduces a further strategic shift through Pacific Software’s acquisition of all outstanding shares of 10763942 Canada Inc. (dba PurMinds NeuroPharma). These updates describe PurMinds as a neuromedicine company with a precision medicine approach and outline an exclusive global partnership with SpectroChip Inc. and SpectroChip Global Inc. to develop photonic chip-based point-of-care testing diagnostics. Readers following PFSF news can therefore expect coverage of corporate acquisitions, licensing agreements, scientific advisory appointments, product development plans, and evolving corporate strategy across restaurant, skincare, dietary supplement, and neuromedicine domains.
Pacific Software (OTC: PFSF) completed a change of control and Reverse Takeover with PurMinds Holdings effective November 3, 2025, and has rebranded to PurMinds Enterprises. The company confirmed occupancy of a 20,477 sq. ft. cGMP-ready pharmaceutical R&D and production facility on January 12, 2026. Management is finalizing a post-RTO capital structure reflecting a 90/10 equity split and issuing common shares to PurMinds shareholders, while resolving legacy transfer agent instructions. The firm filed a FY 2025 Form 10-K (pre-RTO basis) and expects the Dec 31, 2025 10-Q (due Feb 14, 2026) to be the first consolidated filing. The company has started engaging a PCAOB audit firm as a step toward an OTCQX uplisting targeted in H1 2026.
Pacific Software (OTC: PFSF) announced on Nov 11, 2025 the closing of its acquisition of 10763942 Canada Inc. (dba PurMinds NeuroPharma), with PurMinds management assuming leadership roles and a potential corporate name change pending FINRA approval.
PurMinds unveiled an exclusive global partnership with SpectroChip to integrate PurMinds' precision neuromedicine biomarker work with SpectroChip's photonic chip POCT diagnostic platform. The companies said this creates a new revenue pathway with near-term revenue expected in 2026, and aims to support PurMinds' clinical programs with improved patient stratification and longitudinal data collection.
Pacific Software Inc. (OTC:PFSF) has appointed Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA). Dr. Schiestl, a distinguished scientist with over 200 peer-reviewed publications and 16 patents, brings extensive expertise in molecular toxicology, cancer prevention, and genomics. His research focuses on genetic stability and strategies to prevent genetic diseases and cancer, aligning with Pacific Software's mission to develop innovative skincare products and science-based dietary supplements.
Dr. Schiestl's background includes positions at Harvard School of Public Health and UCLA, where he is currently Professor Emeritus. His work on oxidative stress and its health impacts is particularly relevant to Pacific Software's objectives. CEO Harrysen Mittler expressed enthusiasm about Dr. Schiestl's potential contributions to advancing the company's cosmeceutical technology and supplement offerings.
Pacific Software announced the acquisition of a dietary supplement designed to support brain health and memory, marketed as SuppleMEM AD™ and A.L.Z. Defense™.
The formula, tested by leading Alzheimer's researchers, has been sold for over 8 years. The company is obtaining quotes to manufacture this product in the USA and Mexico, targeting distribution in the third quarter of 2024.
This acquisition aligns with Pacific's strategy to diversify into health and skin care products. The core formula, a blend of natural ingredients, has shown positive results in NIH-funded studies at UC Irvine and the University of Kentucky.
The company expects revenue from retail and wholesale channels. Dr. Leissring resigned as president on June 18, 2024.
Pacific Software announced its acquisition of a science-based dietary supplement focused on brain health and memory function, sold under the brand names SuppleMEM AD™ and A.L.Z. Defense™. This acquisition marks Pacific's expansion beyond its previous focus on skin care and wound healing. CEO Harrysen Mittler stated the product has been profitable for over 8 years, and studies funded by the NIH at the University of California, Irvine, and the University of Kentucky have validated its effectiveness. Pacific's President, Dr. Malcolm Leissring, emphasized that proceeds will support the AD Foundation's Alzheimer’s prevention initiatives.
Pacific Software has secured an exclusive licensing agreement with the University of California to develop, manufacture, and commercialize innovative peptide inhibitors of insulin-degrading enzyme (IDE) for skincare and wound healing applications.
The technology, developed with over $6 million in research funding, will be spearheaded by Dr. Malcolm A. Leissring, who will become the Chief Science Officer of Pacific.
The IDE inhibitors, marketed as Dermatrix™, have shown significant capabilities in boosting collagen production, making them revolutionary for both wound healing and cosmetics. The agreement, effective as of March 5, 2024, also makes UC Regents an equity partner in Pacific.
Pacific Software Inc. (PFSF) announced the acquisition of certain assets from Dreamaderm Inc., including a patented cosmeceutical technology called Dermatrix. Dermatrix boosts collagen production by preserving insulin in the skin, offering a wide range of dermatological applications. The technology was developed by Dr. Malcolm A. Leissring and has the potential to revolutionize the cosmetics and skin care industry.
Pacific Software, Inc. (OTCPINK:PFSF) has issued a letter to shareholders highlighting its achievements and future plans. In 2021, the company undertook significant restructuring and made strides in development with multiple joint ventures and acquisitions. Key successes include launching partnerships with Lincoln Clark and Raffaele Gallo, along with a 51% acquisition of a World of Beer tavern. Looking ahead, the company anticipates several new restaurant openings and a rebranding to align with its growth strategy.
Pacific Software, Inc. (OTC PINK:PFSF) announced a debt restructuring of approximately $3,000,000 to enhance its capital structure ahead of its growth initiatives for 2022. The restructuring moves legacy notes from a fixed percentage to a fixed price conversion rate, eliminating liability premiums and interest expenses. This adjustment is expected to simplify accounting and improve financial transparency. The company aims to launch several new restaurant locations and brands soon, indicating a robust growth strategy.
Pacific Software, Inc. (OTCPINK:PFSF) is repositioning to enter the fast casual restaurant market, projected to grow from $125.6 billion in 2019 to $209.1 billion by 2027, at a CAGR of 10.6%.
To spearhead this transition, the company has appointed Isaac Onn as CEO and Michael Finkelstein as COO, both with extensive industry experience. Their strategy includes acquiring restaurant chains affected by the Covid-19 pandemic, aiming to build a diverse cash flow portfolio. The company will also undergo a name change and is launching a new website soon.